

Mark Hatherill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8852161/publications.pdf>

Version: 2024-02-01

121
papers

8,717
citations

71102

41
h-index

48315

88
g-index

126
all docs

126
docs citations

126
times ranked

6885
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Accuracy of the Cepheid 3-gene Host Response Fingerstick Blood Test in a Prospective, Multi-site Study: Interim Results. <i>Clinical Infectious Diseases</i> , 2022, 74, 2136-2141.	5.8	46
2	Molecular Detection of Airborne <i>Mycobacterium tuberculosis</i> in South African High Schools. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 350-356.	5.6	10
3	The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study. <i>Vaccine</i> , 2022, 40, 364-369.	3.8	1
4	Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studies. <i>EBioMedicine</i> , 2022, 76, 103839.	6.1	19
5	REL and BHLHE40 Variants Are Associated with IL-12 and IL-10 Responses and Tuberculosis Risk. <i>Journal of Immunology</i> , 2022, 208, 1352-1361.	0.8	6
6	Correlation Between CT Features of Active Tuberculosis and Residual Metabolic Activity on End-of-Treatment FDG PET/CT in Patients Treated for Pulmonary Tuberculosis. <i>Frontiers in Medicine</i> , 2022, 9, 791653.	2.6	2
7	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. <i>EBioMedicine</i> , 2022, 77, 103886.	6.1	2
8	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. <i>Communications Medicine</i> , 2022, 2, .	4.2	15
9	Clinical predictors of pulmonary tuberculosis among South African adults with HIV. <i>EClinicalMedicine</i> , 2022, 45, 101328.	7.1	7
10	Accelerating research and development of new vaccines against tuberculosis: a global roadmap. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e108-e120.	9.1	28
11	Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study. <i>EClinicalMedicine</i> , 2022, 47, 101396.	7.1	3
12	<i>Mycobacterium tuberculosis</i> infection, immune activation, and risk of HIV acquisition. <i>PLoS ONE</i> , 2022, 17, e0267729.	2.5	2
13	Non-volatile organic compounds in exhaled breath particles correspond to active tuberculosis. <i>Scientific Reports</i> , 2022, 12, 7919.	3.3	3
14	End-point definition and trial design to advance tuberculosis vaccine development. <i>European Respiratory Review</i> , 2022, 31, 220044.	7.1	7
15	Immune Profiling Enables Stratification of Patients With Active Tuberculosis Disease or <i>Mycobacterium tuberculosis</i> Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e3398-e3408.	5.8	18
16	Immune profiling of <i>Mycobacterium tuberculosis</i> -specific T cells in recent and remote infection. <i>EBioMedicine</i> , 2021, 64, 103233.	6.1	17
17	Inflammatory Determinants of Differential Tuberculosis Risk in Pre-Adolescent Children and Young Adults. <i>Frontiers in Immunology</i> , 2021, 12, 639965.	4.8	7
18	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 354-365.	9.1	84

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of the adjunct therapeutic vaccine ID93+GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 373-386.	10.7	46
20	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. <i>The Lancet Global Health</i> , 2021, 9, e841-e853.	6.3	34
21	Antigen-Specific T-Cell Activation Distinguishes between Recent and Remote Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1556-1565.	5.6	25
22	Multidimensional analysis of immune responses identified biomarkers of recent <i>Mycobacterium tuberculosis</i> infection. <i>PLoS Computational Biology</i> , 2021, 17, e1009197.	3.2	1
23	Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e048623.	1.9	5
24	<i>Mycobacterium tuberculosis</i> -Specific T Cell Functional, Memory, and Activation Profiles in QuantiFERON-Reverters Are Consistent With Controlled Infection. <i>Frontiers in Immunology</i> , 2021, 12, 712480.	4.8	8
25	Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1463-1472.	5.6	15
26	The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study. <i>BMC Medicine</i> , 2021, 19, 252.	5.5	4
27	¹⁸ F-FDG PET/CT as a Noninvasive Biomarker for Assessing Adequacy of Treatment and Predicting Relapse in Patients Treated for Pulmonary Tuberculosis. <i>Journal of Nuclear Medicine</i> , 2020, 61, 412-417.	5.0	23
28	Postnatal Expansion, Maturation, and Functionality of MR1T Cells in Humans. <i>Frontiers in Immunology</i> , 2020, 11, 556695.	4.8	14
29	Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines. <i>Communications Biology</i> , 2020, 3, 563.	4.4	14
30	Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0237574.	2.5	39
31	Immune serum-activated human macrophages coordinate with eosinophils to immobilize <i>Ascaris suum</i> larvae. <i>Parasite Immunology</i> , 2020, 42, e12728.	1.5	11
32	Blood transcriptional signatures for tuberculosis testing. <i>Lancet Respiratory Medicine</i> , 2020, 8, 330-331.	10.7	6
33	Regional changes in tuberculosis disease burden among adolescents in South Africa (2005-2015). <i>PLoS ONE</i> , 2020, 15, e0235206.	2.5	5
34	Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy <i>Mycobacterium tuberculosis</i> -Exposed Controls. <i>Journal of Infectious Diseases</i> , 2020, 222, 995-1007.	4.0	19
35	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. <i>Scientific Reports</i> , 2020, 10, 8629.	3.3	90
36	Sample adequacy controls for infectious disease diagnosis by oral swabbing. <i>PLoS ONE</i> , 2020, 15, e0241542.	2.5	14

#	ARTICLE	IF	CITATIONS
37	Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 220-231.	5.6	75
38	Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. <i>Scientific Reports</i> , 2019, 9, 11126.	3.3	13
39	Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategies. <i>Lancet Respiratory Medicine</i> , 2019, 7, 544-552.	10.7	52
40	Final Analysis of a Trial of M72/AS01 Vaccine to Prevent Tuberculosis. <i>New England Journal of Medicine</i> , 2019, 381, 2429-2439.	27.0	350
41	Live-attenuated <i>Mycobacterium tuberculosis</i> vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 757-770.	10.7	92
42	Plasma Type I IFN Protein Concentrations in Human Tuberculosis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 296.	3.9	10
43	Diagnostic Accuracy of Early Secretory Antigenic Target-6 Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube. <i>Clinical Infectious Diseases</i> , 2019, 69, 1724-1730.	5.8	12
44	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16
45	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. <i>Frontiers in Microbiology</i> , 2019, 10, 1441.	3.5	46
46	Performance of host blood transcriptomic signatures for diagnosing and predicting progression to tuberculosis disease in HIV-negative adults and adolescents: a systematic review protocol. <i>BMJ Open</i> , 2019, 9, e026612.	1.9	7
47	Addressing critical needs in the fight to end tuberculosis with innovative tools and strategies. <i>PLoS Medicine</i> , 2019, 16, e1002795.	8.4	7
48	Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002781.	8.4	72
49	A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates. <i>PLoS Pathogens</i> , 2019, 15, e1007643.	4.7	79
50	MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by <i>Mycobacteria</i> . <i>Journal of Immunology</i> , 2019, 203, 2917-2927.	0.8	55
51	Noninvasive Detection of Tuberculosis by Oral Swab Analysis. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	50
52	Advances in the understanding of <i>Mycobacterium tuberculosis</i> transmission in HIV-endemic settings. <i>Lancet Infectious Diseases</i> , 2019, 19, e65-e76.	9.1	35
53	Safety and Immunogenicity of Early <i>Bacillus Calmette-Guérin</i> Vaccination in Infants Who Are Preterm and/or Have Low Birth Weights. <i>JAMA Pediatrics</i> , 2019, 173, 75.	6.2	18
54	Clinical Development of New TB Vaccines: Recent Advances and Next Steps. <i>Frontiers in Microbiology</i> , 2019, 10, 3154.	3.5	56

#	ARTICLE	IF	CITATIONS
55	Cytomegalovirus infection is a risk factor for tuberculosis disease in infants. JCI Insight, 2019, 4, .	5.0	42
56	Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1198-1208.	5.6	217
57	Safety and immunogenicity of the novel tuberculosis vaccine ID93+GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respiratory Medicine, 2018, 6, 287-298.	10.7	122
58	T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation. European Respiratory Journal, 2018, 51, 1800153.	6.7	65
59	Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cells. Tuberculosis, 2018, 108, 124-126.	1.9	49
60	120. A Randomized Double-blind Trial Assessing the Efficacy of M72/AS01E Vaccine Against Pulmonary Tuberculosis Disease in Adults With Latent Mycobacterium tuberculosis Infection. Open Forum Infectious Diseases, 2018, 5, S5-S6.	0.9	0
61	Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. Clinical Infectious Diseases, 2018, 66, 554-563.	5.8	32
62	Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria. PLoS ONE, 2018, 13, e0208940.	2.5	12
63	Phase 2b Controlled Trial of M72/AS01 Vaccine to Prevent Tuberculosis. New England Journal of Medicine, 2018, 379, 1621-1634.	27.0	319
64	Progress and challenges in TB vaccine development. F1000Research, 2018, 7, 199.	1.6	93
65	Elevated IgG Responses in Infants Are Associated With Reduced Prevalence of Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2018, 9, 1529.	4.8	16
66	Functional, Antigen-Specific Stem Cell Memory (TSCM) CD4+ T Cells Are Induced by Human Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2018, 9, 324.	4.8	44
67	Prevention of <i>M. tuberculosis</i> Infection with H4:IC31 Vaccine or BCG Revaccination. New England Journal of Medicine, 2018, 379, 138-149.	27.0	532
68	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis, 2018, 109, 61-68.	1.9	28
69	POLICY-DRIVEN INTERVENTIONS: TUBERCULOSIS. BMJ Global Health, 2017, 2, A4.1-A4.	4.7	0
70	Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine, 2017, 5, 282-290.	10.7	110
71	The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomes. Tuberculosis, 2017, 104, 38-45.	1.9	16
72	Prevalence of latent TB infection and TB disease among adolescents in high TB burden countries in Africa: a systematic review protocol. BMJ Open, 2017, 7, e014609.	1.9	3

#	ARTICLE	IF	CITATIONS
73	A Functional Toll-Interacting Protein Variant Is Associated with <i>Bacillus Calmette-Guérin</i> -Specific Immune Responses and Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 502-511.	5.6	38
74	Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. <i>Cell Host and Microbe</i> , 2017, 21, 695-706.e5.	11.0	164
75	Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of <i>Mycobacterium tuberculosis</i> Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 638-648.	5.6	124
76	Differential Recognition of <i>Mycobacterium tuberculosis</i> -Specific Epitopes as a Function of Tuberculosis Disease History. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 772-781.	5.6	39
77	H1:IC31 vaccination is safe and induces long-lived TNF- α +IL-2+CD4 T cell responses in <i>M. tuberculosis</i> infected and uninfected adolescents: A randomized trial. <i>Vaccine</i> , 2017, 35, 132-141.	3.8	34
78	Clinical Testing of Tuberculosis Vaccine Candidates. , 2017, , 193-211.		1
79	Application of a whole blood mycobacterial growth inhibition assay to study immunity against <i>Mycobacterium tuberculosis</i> in a high tuberculosis burden population. <i>PLoS ONE</i> , 2017, 12, e0184563.	2.5	14
80	Sequential inflammatory processes define human progression from <i>M. tuberculosis</i> infection to tuberculosis disease. <i>PLoS Pathogens</i> , 2017, 13, e1006687.	4.7	193
81	Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. <i>Gates Open Research</i> , 2017, 1, 9.	1.1	22
82	Clinical Testing of Tuberculosis Vaccine Candidates. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	24
83	BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2016, 62, S262-S267.	5.8	13
84	Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review. <i>International Journal of Epidemiology</i> , 2016, 45, 580-580.	1.9	1
85	Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study. <i>BMC Medicine</i> , 2016, 14, 76.	5.5	55
86	<i>Bacillus Calmette-Guérin</i> (BCG) Revaccination of Adults with Latent <i>Mycobacterium tuberculosis</i> Infection Induces Long-Lived BCG-Reactive NK Cell Responses. <i>Journal of Immunology</i> , 2016, 197, 1100-1110.	0.8	121
87	T-cell activation is an immune correlate of risk in BCG vaccinated infants. <i>Nature Communications</i> , 2016, 7, 11290.	12.8	236
88	Predicting tuberculosis risk - Authors' reply. <i>Lancet</i> , The, 2016, 388, 2233-2234.	13.7	12
89	A blood RNA signature for tuberculosis disease risk: a prospective cohort study. <i>Lancet</i> , The, 2016, 387, 2312-2322.	13.7	678
90	A Quantitative Analysis of Complexity of Human Pathogen-Specific CD4 T Cell Responses in Healthy <i>M. tuberculosis</i> Infected South Africans. <i>PLoS Pathogens</i> , 2016, 12, e1005760.	4.7	128

#	ARTICLE	IF	CITATIONS
91	The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. <i>Vaccine</i> , 2015, 33, 3592-3599.	3.8	71
92	Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN- γ in QuantiFERON assays in healthy persons. <i>Tuberculosis</i> , 2015, 95, 350-351.	1.9	12
93	First-in-human trial of a live-attenuated Mycobacterium tuberculosis vaccine. <i>Lancet Respiratory Medicine</i> , 2015, 3, 906-907.	10.7	1
94	The Dynamics of QuantiFERON-TB Gold In-Tube Conversion and Reversion in a Cohort of South African Adolescents. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 584-591.	5.6	108
95	First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. <i>Vaccine</i> , 2015, 33, 4130-4140.	3.8	183
96	A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe. <i>Vaccine</i> , 2015, 33, 4719-4726.	3.8	17
97	Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. <i>Vaccine</i> , 2015, 33, 4025-4034.	3.8	110
98	Evaluation of Xpert [®] MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial. <i>PLoS ONE</i> , 2015, 10, e0141623.	2.5	19
99	The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses. <i>PLoS ONE</i> , 2014, 9, e87340.	2.5	79
100	Tuberculosis Vaccines and Prevention of Infection. <i>Microbiology and Molecular Biology Reviews</i> , 2014, 78, 650-671.	6.6	133
101	Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. <i>Vaccine</i> , 2014, 32, 3982-3988.	3.8	33
102	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. <i>New England Journal of Medicine</i> , 2014, 371, 1599-1608.	27.0	383
103	Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response. <i>BMC Infectious Diseases</i> , 2014, 14, 314.	2.9	24
104	The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses. <i>Vaccine</i> , 2014, 32, 5908-5917.	3.8	41
105	Screening for TB in high school adolescents in a high burden setting in South Africa. <i>Tuberculosis</i> , 2013, 93, 357-362.	1.9	21
106	Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. <i>Tuberculosis</i> , 2013, 93, 143-149.	1.9	35
107	Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2013, 381, 1021-1028.	13.7	903
108	Consensus Statement on Diagnostic End Points for Infant Tuberculosis Vaccine Trials. <i>Clinical Infectious Diseases</i> , 2012, 54, 493-501.	5.8	19

#	ARTICLE	IF	CITATIONS
109	A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or <i>Mycobacterium tuberculosis</i> -infected Adults. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 769-778.	5.6	78
110	Phenotypic variability in childhood TB: Implications for diagnostic endpoints in tuberculosis vaccine trials. <i>Vaccine</i> , 2011, 29, 4316-4321.	3.8	14
111	The Tuberculin Skin Test versus QuantiFERON TB Gold® in Predicting Tuberculosis Disease in an Adolescent Cohort Study in South Africa. <i>PLoS ONE</i> , 2011, 6, e17984.	2.5	119
112	Prospects for elimination of childhood tuberculosis: the role of new vaccines. <i>Archives of Disease in Childhood</i> , 2011, 96, 851-856.	1.9	17
113	Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4 ⁺ T cells. <i>European Journal of Immunology</i> , 2010, 40, 279-290.	2.9	171
114	The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4 ⁺ and CD8 ⁺ T Cells in Adults. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1407-1417.	5.6	211
115	Specific T Cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis after Bacillus Calmette-Guérin Vaccination of Newborns. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1073-1079.	5.6	386
116	Novel vaccine prime and selective BCG boost: A new tuberculosis vaccine strategy for infants of HIV-infected mothers. <i>Vaccine</i> , 2010, 28, 4550-4552.	3.8	6
117	Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa. <i>Bulletin of the World Health Organization</i> , 2010, 88, 312-320.	3.3	62
118	Comparison of Mantoux and Tine Tuberculin Skin Tests in BCG-Vaccinated Children Investigated for Tuberculosis. <i>PLoS ONE</i> , 2009, 4, e8085.	2.5	9
119	Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. <i>BMJ: British Medical Journal</i> , 2008, 337, a2052-a2052.	2.3	90
120	The lactate:pyruvate ratio following open cardiac surgery in children. <i>Intensive Care Medicine</i> , 2007, 33, 822-829.	8.2	17
121	Isolation of Non-Tuberculous Mycobacteria in Children Investigated for Pulmonary Tuberculosis. <i>PLoS ONE</i> , 2006, 1, e21.	2.5	28